XML 50 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements Of Cash Flows (USD $)
 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Cash Flows from Operating Activities:    
Net income $ 156,000,000 $ 144,557,000
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 43,610,000 41,130,000
Provision for uncollectible accounts 1,678,000 1,226,000
Benefit of deferred income taxes (6,729,000) (984,000)
Share-based compensation expense 13,463,000 12,265,000
Other (79,000) 446,000
Tax benefit from share-based compensation arrangements (9,581,000) (7,438,000)
Changes in assets and liabilities:    
Accounts receivable (8,464,000) (12,795,000)
Inventories (12,638,000) (10,216,000)
Other assets (3,375,000) 4,717,000
Accounts payable 6,876,000 3,958,000
Accrued liabilities 16,216,000 (335,000)
Deferred revenue 11,566,000 4,050,000
Net cash provided by operating activities 208,543,000 180,581,000
Cash Flows from Investing Activities:    
Purchases of property and equipment (42,504,000) (61,459,000)
Proceeds from disposition of pharmaceutical product lines   3,500,000
Proceeds from sale of equity investment 5,400,000  
Acquisitions of intangible assets (175,000) (1,024,000)
Acquisitions of a business, net of cash acquired (7,516,000) (10,101,000)
Net cash used by investing activities (44,795,000) (69,084,000)
Cash Flows from Financing Activities:    
Borrowings on revolving credit facilities, net 98,000,000 185,200,000
Issuance of senior notes 200,000,000  
Debt issue costs (1,357,000)  
Payment of notes payable (1,394,000) (858,000)
Repurchases of common stock (468,968,000) (282,910,000)
Proceeds from exercises of stock options and employee stock purchase plans 18,361,000 21,734,000
Tax benefit from share-based compensation arrangements 9,581,000 7,438,000
Net cash (used) provided by financing activities (145,777,000) (69,396,000)
Net effect of changes in exchange rates on cash (4,294,000) (1,276,000)
Net increase in cash and cash equivalents 13,677,000 40,825,000
Cash and cash equivalents at beginning of period 279,058,000 223,986,000
Cash and cash equivalents at end of period 292,735,000 264,811,000
Supplemental Disclosure of Non-Cash Information:    
Market value of common shares received from employees in connection with share-based compensation - see Note 18 $ 5,300,000 $ 4,300,000